Michael Ashton
Professor of Clinical Pharmacology at the University of Gothenburg
Data updated
Research Footprint
Michael Ashton appears in 7 tracked papers (2018–2025), most studied alongside DMT, Psilocybin and Placebo, across Medicinal Chemistry & Drug Development, Healthy Volunteers and Depressive Disorders.
Most-cited paper: Neural correlates of the DMT experience assessed with multivariate EEG (321 citations).
Frequent co-authors: Robin Carhart-Harris, Christopher Timmermann and Emma Eckernäs.
Background & Research
Michael Ashton is a professor at the Department of Pharmacology at the University of Gothenburg. His research background is in clinical pharmacokinetics, pharmacogenetics, and pharmacometrics, and he has coauthored recent studies on DMT metabolism, exposure-response relationships, and dose optimization in psychedelic research. He also appears as a coauthor on psilocybin-related work involving prediction of treatment response from baseline speech data.
Key Impact
He is a pharmacometrics and clinical pharmacology researcher whose work has been used in psychedelic studies on DMT pharmacokinetics, pharmacodynamics, EEG effects, and psychedelic intensity modeling.
Collaboration Network
17 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Michael Ashton is associated with.